Structure Therapeutics (GPCR) Projected to Post Quarterly Earnings on Wednesday

Structure Therapeutics (NASDAQ:GPCR) is expected to issue its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter. Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 13, 2025 at 4:00 PM ET.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.08). On average, analysts expect Structure Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Structure Therapeutics Stock Up 3.8%

Shares of GPCR opened at $34.01 on Wednesday. Structure Therapeutics has a 12-month low of $13.22 and a 12-month high of $42.20. The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of -32.39 and a beta of -1.64. The stock’s 50-day moving average price is $25.51 and its 200 day moving average price is $22.76.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on GPCR. Piper Sandler restated an “overweight” rating on shares of Structure Therapeutics in a research report on Tuesday, October 28th. HC Wainwright lowered their price target on shares of Structure Therapeutics from $75.00 to $60.00 and set a “buy” rating on the stock in a report on Thursday, August 7th. Lifesci Capital raised shares of Structure Therapeutics to a “strong-buy” rating in a research note on Monday, September 8th. Zacks Research cut shares of Structure Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Friday, October 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $68.67.

Institutional Investors Weigh In On Structure Therapeutics

Several large investors have recently made changes to their positions in the company. State of Wyoming bought a new stake in Structure Therapeutics during the second quarter worth about $28,000. Raymond James Financial Inc. bought a new stake in Structure Therapeutics during the 2nd quarter worth approximately $129,000. Engineers Gate Manager LP bought a new stake in Structure Therapeutics during the 2nd quarter worth approximately $329,000. Envestnet Asset Management Inc. grew its position in Structure Therapeutics by 14.5% during the 3rd quarter. Envestnet Asset Management Inc. now owns 12,220 shares of the company’s stock worth $342,000 after acquiring an additional 1,544 shares during the last quarter. Finally, Paloma Partners Management Co bought a new stake in Structure Therapeutics during the 2nd quarter worth approximately $435,000. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.